Canadian hydropower producer upgrades timing network with Adtran’s Oscilloquartz optical cesium clock
Adtran today announced that a leading Canadian hydropower producer is using its Oscilloquartz grandmaster device combined with its optical cesium atomic clock to achieve new levels of precision, reliability and resilience in its power grid synchronization network. The deployment addresses the urgent need to implement the highest standards of protection against GNSS disruptions, including jamming and spoofing cyberattacks, and helps bolster North America’s energy resilience. Featuring multi-source protection, the enhanced timing architecture offers a zero-trust approach to positioning, navigation and timing (PNT), ensuring robust and accurate synchronization. It also seamlessly supports existing services, enabling a smooth transition from legacy timing to power grids with advanced PTP technology. For streamlined operations and assurance, the synchronization network is remotely managed through the Adtran Ensemble Controller with Sync Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502346533/en/
Adtran’s Oscilloquartz timing technology is playing a key role in protecting Canadian hydropower producer from GNSS cyberattacks. (Photo: Business Wire)
“It’s great to be helping another major utility to modernize its timing infrastructure and prepare for next-generation smart grid applications. The transition from traditional TDM to advanced packet-based synchronization marks a significant milestone for this forward-thinking power supplier. The solution will also strengthen its timing network against the growing dangers of relying solely on GNSS,” commented John Scherzinger, GM of Americas sales at Adtran. “The deployment of our advanced grandmaster clock enables the utility to extend reliable timing to Canada’s most remote regions. The superior stability and precision of our optical cesium clock are key to realizing levels of accuracy and resilience never seen before. What’s more, our Ensemble Sync Director system brings the benefits of centralized control, ensuring comprehensive monitoring and simplified operational management. This is essential for maintaining the reliability and security of the utility’s extensive and often remotely located network.”
By enhancing its timing framework with Adtran’s Oscilloquartz solution, the hydroelectric producer is ensuring it maintains the highest standards of cybersecurity and energy reliability in its critical infrastructure. The deployment will also improve the stability and security of the energy supply across Canada and the US. The new solution includes Adtran’s OSA 3350 ePRC+ combined with its highly versatile OSA 5422 to provide the highest precision, stability and resilience against GNSS vulnerabilities. Featuring an all-digital design, the OSA 3350 ePRC+ utilizes optical-pumping techniques, guaranteeing timing accuracy and optimal stability for over a decade – twice the lifespan of conventional cesium clocks. Together with the OSA 5422, the solution future-proofs the utility’s timing network and assures compliance with governmental regulations. It also fortifies security and underscores the renewable energy utility’s commitment to maintaining a continuous, secure power supply.
“This leading Canadian power supplier is renowned for its dedication to innovation. Its choice to adopt our technology highlights both the impact of our solution and its significance on a global scale. By transitioning its substation network from traditional TDM to advanced packet-based synchronization, it’s setting a precedent for the entire industry to follow,” commented Gil Biran, GM of Oscilloquartz, Adtran. “Our solution offers robust defense against GNSS vulnerabilities and ensures adherence to stringent industry regulations. Through our ongoing support, the utility is reinforcing its dedication to enhancing both resilience and reliability – elements that are fundamental for fulfilling PNT requirements. This is crucial for safeguarding the integrity of critical network infrastructure, ensuring a consistent and dependable energy future for all.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502346533/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 20245.11.2024 15:05:00 CET | Press Release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cell malignancies and assets, including best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib), at the 66th ASH Annual Meeting and Exposition in San Diego, December 7-10. BeiGene has 21 abstracts accepted at ASH 2024, with four selected for oral presentation. “In the five years since its initial approval, BRUKINSA has become a standard of care for patients facing many B-cell malignancies, and our data featured at ASH demonstrated how long-term follow-up of treatment with BRUKINSA elicited deep and durable responses, including in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia,” said Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “BRUKINSA is just the starting point – pipeline data for our BTK degrader BGB-16673 and BCL2 inhibitor sonrotoclax showcase our contin
DirectSens’ Market-Leading LactoSens ® Biosensor Technology Acquired by Kerry Group P.L.C.5.11.2024 14:00:00 CET | Press Release
DirectSens, a pioneer in next generation biosensor technology, announces the acquisition of its LactoSens® technology by Kerry Group, a global leader in taste and nutrition. The acquisition of LactoSens® reflects DirectSens’ success in developing end-to-end biosensor solutions and represents a move by Kerry Group to complement its offering in lactase enzymes. As an indispensable analytical tool, LactoSens® will work alongside Kerry Group’s ingredient solutions, enabling a more integrated offering for food manufacturers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241105399369/en/ LactoSens®, Industry Gold Standard Biosensor Kit. Developed and manufactured by DirectSens in Vienna, AUSTRIA, © DirectSens GmbH 2024 “We’re excited to bring LactoSens® into Kerry Group’s portfolio to add a new element to our offering, as we fully integrate LactoSens® into our broader solutions for the food and beverage industry.” — Ronan Moloney
Technology Holdings Has Expanded Operations into Brazil, Driving Growth in Latin America5.11.2024 13:35:00 CET | Press Release
Technology Holdings (TH), an award-winning global boutique investment bank with a track record of closing transactions in 24 countries, proudly announces its strategic expansion into Brazil, leveraging digital transformation within one of Latin America’s largest economies. This move significantly strengthens Technology Holdings’ presence in the rapidly growing Latin American market, enabling the firm to play a vital role in the region's expanding M&A landscape. According to Dealogic, M&A deals totaling $35 billion have been announced, reflecting a 56% increase compared to the same period last year. As companies increasingly look to consolidate and expand, Technology Holdings is uniquely positioned to provide strategic guidance and facilitate successful transactions. “The expansion into Brazil represents an exciting opportunity for us to deepen our relationships within this vibrant market,” said Edoardo Freschet, Head of Latin America at Technology Holdings. “The quality of talent and t
EUMETSAT: Lisbon Event Offers a Deep Dive Into Ocean Data5.11.2024 13:07:00 CET | Press Release
People with an interest in our oceans – from academics to businesspeople through to representatives from navies and weather services – are meeting in Lisbon, Portugal, for a deep dive into satellite data and its uses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241105106009/en/ (Photo: Business Wire) Europe’s meteorological satellite agency, EUMETSAT, the European Commission, the European Space Agency, the European Centre for Medium-Range Weather Forecasts and Mercator Ocean International are hosting the two-day event starting today. The aim is to showcase how data from the Copernicus Sentinel satellites are used to benefit agencies and businesses with an interest in the marine environment, to connect data users with different skills and expertise, and to receive feedback on how to better meet the needs of existing and potential data users. “What happens in our oceans influences everyone’s lives by impacting our weather,
Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-149275.11.2024 12:00:00 CET | Press Release
We are excited to share our latest development status. As informed dated October 28th, an interim analysis for the Phase III study ofDFP-10917 in R/R AML patients is ongoing. The Phase I/II combination study of DFP-10917 with Venetoclax in AML patients is well ongoing. Today, we are delighted to talk about an update for development of the drug delivery of DFP-10917 selective to solid tumor, which is namely, DFP-14927 showed nice safety and efficacy in the Phase I study in solid tumor patients. Accordingly, we have moved forward into an expanded Phase I study of DFP-14927 at 3200 mg/m2 weekly dosing in R/R colorectal cancer patients at MD Anderson Cancer Center and UCLA. Efficacy in expanded Phase I study is evaluated by Disease Control Ratio (DCR) and it shall be evaluated by OS in the next registration study for NDA approval. View source version on businesswire.com: https://www.businesswire.com/news/home/20241105884234/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom